Status:
UNKNOWN
Risk-Reducing Surgeries for Hereditary Ovarian Cancer
Lead Sponsor:
Lei Li
Conditions:
Hereditary Breast and Ovarian Cancer Syndrome
Colorectal Neoplasms, Hereditary Nonpolyposis
Eligibility:
FEMALE
35+ years
Phase:
NA
Brief Summary
Based on studies of "Inherited Susceptible Genes Among Epithelial Ovarian Cancer" (NCT03015376, clinicaltrials.gov) and "Cohort Study of Universal Screening for Lynch Syndrome in Chinese Patients of E...
Eligibility Criteria
Inclusion
- Carriers with known and definite mutation genes of hereditary ovarian cancer.
- With children and without further requirement of pregnancy.
- No less than 35 years for carriers with mutation gene of BRCA1.
- No less than 40 years for carriers with mutation gene of BRCA2.
- No less than 45 years for carriers with mutation genes of BRIP1, RAD51C, RAD51D and RAD51.
- No less than 50 years for carriers with mutation genes of ATM, MSH2, MLH1, SH6, PMS2, EPCAM and STK11.
Exclusion
- Without children.
- Not reaching appreciate ages.
- With contraindications of laparoscopy.
- Refusal of risk-reducing surgeries.
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT03294343
Start Date
September 1 2017
End Date
September 1 2023
Last Update
December 26 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lei Li
Beijing, China/Beiing, China, 100000